Shares of VIVUS, Inc. (NASDAQ:VVUS) were down 6.8% on Tuesday . The stock traded as low as $0.81 and last traded at $0.82. Approximately 954,087 shares traded hands during mid-day trading, a decline of 11% from the average daily volume of 1,076,384 shares. The stock had previously closed at $0.88.
Several analysts have recently weighed in on VVUS shares. Zacks Investment Research upgraded shares of VIVUS from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a research note on Wednesday, May 16th. ValuEngine upgraded shares of VIVUS from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd.
The company has a market cap of $90.35 million, a price-to-earnings ratio of -2.82 and a beta of 0.83. The company has a current ratio of 8.67, a quick ratio of 7.94 and a debt-to-equity ratio of -12.06.
VIVUS (NASDAQ:VVUS) last announced its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.01. The business had revenue of $11.90 million during the quarter. VIVUS had a negative net margin of 79.80% and a negative return on equity of 843.43%. equities analysts expect that VIVUS, Inc. will post -0.43 earnings per share for the current year.
In other VIVUS news, Director Herm Rosenman purchased 100,000 shares of the firm’s stock in a transaction on Monday, May 21st. The stock was acquired at an average price of $0.81 per share, for a total transaction of $81,000.00. Following the purchase, the director now owns 136,671 shares of the company’s stock, valued at approximately $110,703.51. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John P. Amos purchased 270,000 shares of the firm’s stock in a transaction on Friday, May 18th. The shares were acquired at an average price of $0.77 per share, with a total value of $207,900.00. Following the purchase, the chief executive officer now directly owns 1,710,000 shares in the company, valued at approximately $1,316,700. The disclosure for this purchase can be found here. Insiders have acquired a total of 1,820,000 shares of company stock valued at $1,090,500 in the last 90 days. 4.40% of the stock is currently owned by company insiders.
VIVUS, Inc, a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.